Optimizing Mycoplasma Detection: The Benefits of DNA-Based Testing

Mycoplasma contamination in biopharmaceutical production is a critical concern, with significant implications for both product safety and efficacy. This webinar explores the use of DNA as an advanced analyte for Mycoplasma testing, providing an in-depth comparison between traditional approaches and DNA-based methods. Our expert speaker will outline the benefits and broader applications of DNA analysis, including technology transfer and other critical processes in biopharmaceutical manufacturing. Attendees will also gain insights into how to implement DNA-based testing in manufacturing processes. 1. Understand the threat of Mycoplasma contamination in biopharmaceutical processes 2. Gain an overview of how DNA serves as a robust biological marker for the presence of Mycoplasma 3. Learn how to navigate the regulatory landscape for DNA-based Mycoplasma testing, including compliance with guidelines 4. Explore practical applications of DNA-based testing facilitating Mycoplasma testing Sharon Rouw Product Manager, BioProduction Group Choose an item. Other: Thermo Fisher Scientific, Inc. Sharon.Rouw@thermofisher.com   Sharon Rouw is a Senior Product Manager with the BioProduction Group (BPG) at Thermo Fisher Scientific. She is part of the Pharma Analytics business, a team responsible for development and commercialization of testing applications for Microbiology, Analytical Sciences and Quality Control. The products are fully integrated solutions for Bacterial and Fungal identification, Mycoplasma and Viral detection and host cell DNA and protein quantitation. In this role, Sharon is responsible for managing the MycoSEQ™ Mycoplasma Detection products used by BioProduction customers worldwide. Sharon has over 20 years’ experience across the biopharma, pharma and life science industries. Prior to joining Thermo Fisher Scientific, she served in a variety of roles including product management, marketing management and R&D for companies such as MilliporeSigma, Integrated DNA Technologies and Pfizer. Sharon holds a master’s degree in cell & molecular biology and an MBA from Washington University.